To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".
|
MabCampath
|
| see alemtuzumab 29(6) 167-71 |
|
Mabthera
|
| see rituximab 22(1) 20-3 |
|
macrocytosis
|
| folates and vitamin B 22(1) 16-8 |
|
macular degeneration
|
| anecortave - Retaane (New drug) 29(2) 53-5 |
| drug treatment 25(5) 116-9 |
| patient support organisations 25(5) 115 |
| ranibizumab - Lucentis (New drug) 30(3) 79-82 |
| verteporfin - Visudyne (New drug) 23(6) 137-9 |
|
Madopar
|
| see levodopa 21(2) 49-55 |
|
magnesium
|
| abnormal laboratory results 30(4) 102-5 |
| letter 30(6) 140-41 |
|
magnetic resonance angiography
|
| cerebrovascular imaging 24(6) 134; 24(6) 137-40; 24(6) 141-3 |
| in neuroradiology 31(1) 18-20 |
|
magnetic resonance imaging
|
| disodium gadoxetate - Primovist - liver imaging (New drug) 29(3) 84-7 |
| gadobenate dimeglumine - MultiHance (New drug) 27(6) 159-65 |
| gadodiamide - contrast medium - Omniscan (New drug) 17(2) 30-2 |
| gadoteric acid - contrast medium - Dotarem (New drug) 25(6) 147-51 |
| gadoteridol - contrast medium - Prohance (New drug) 25(2) 44-7 |
| gadoversetamide - contrast medium - OptiMARK (New drug) 24(3) 71-5 |
|
malaria
|
| artemether/lumefantrine combination - Riamet (New drug) 26(3) 68-71 |
| primaquine - Primacin (New drug) 22(3) 70-1 |
| letter 22(5) 103-5 |
| travel health (letter) 17(3) 55-6 |
| travel medicine 25(3) 66-9 |
| letter 25(6) 131-2 |
|
maldison
|
| pediculosis capitis 23(3) 62-3 |
| letters 24(1) 3; 23(5) 93-6 |
|
malnutrition
|
| management 24(5) 113-5 |
| and surgical outcomes 26(6) 136-40 |
|
mammography
|
| breast cancer prevention 25(6) 139-41 |
|
manic depressive illness
|
| zuclopenthixol - Clopixol-Acuphase (New drug) 19(2) 38-40 |
|
Mantoux test
|
| BCG vaccine 26(6) 144-6; 26(6) 146 |
| letters 27(2) 28-33 |
|
Marevan
|
| see warfarin 26(2) 27-9; 22(5) 103-5; 21(3) 60-3; 20(4) 83-6; 20(2) 33-4; 19(1) 6-7 |
|
mass media
|
| Media Doctor - website review 28(1) 13 |
|
Maxamox
|
| see amoxycillin 27(1) 21-3 |
|
Maxipime
|
| see cefepime 21(3) 80-3 |
|
measles
|
| childhood immunisation 17(4) 91-4 |
|
measles, mumps, rubella vaccine
|
| Priorix (New formulation) 22(4) 95-8 |
|
Media Doctor
|
| website review 28(1) 13 |
|
media reporting on medical issues
|
| editorial 23(4) 70-1 |
| letter 23(6) 115-7 |
|
medical technology
|
| high cost (editorial) 17(3) 54-5 |
| letters 18(2) 27-9 |
|
MedicAlert
|
| letter 18(4) 84-6 |
|
medication histories
|
| recognising drug adverse effects 25(3) 73-4 |
| letter 25(5) 104-7 |
|
medication reviews
|
| letter 17(4) 79-81 |
|
medicinal mishap
|
| bisphosphonates and osteonecrosis of the jaws 30(4) 96-7 |
| brand confusion with digoxin 29(6) 153 |
| cabergoline-induced valvulopathy 31(1) 21 |
| cross-reactivity of penicillins and cephalosporins 30(1) 25-6 |
| dosing errors with infant drops 29(3) 83 |
| fenofibrate-warfarin interaction 29(6) 166 |
| hyponatraemia and omeprazole 28(2) 48-9 |
| ibuprofen and asthma 27(4) 87 |
| interstitial nephritis and omeprazole 30(3) 67 |
| miconazole gel - warfarin interaction 26(2) 35 |
| neutropenia with quetiapine 31(1) 10-11 |
| serotonin syndrome and over-the-counter medicine 29(3) 71 |
| 'statins' and muscle symptoms 28(4) 102 |
| letter 28(6) 136-9 |
| tramadol and hyponatraemia 27(4) 97 |
|
Medicines Australia (see also APMA)
|
| code of conduct breaches 30(6) 153-5; 29(6) 164-5; 29(1) 16-7; 27(6) 141; 27(3) 60; 27(1) 6-7; 26(3) 66; 26(3) 67 |
| vardenafil 30(6) 154 |
| declarations of interest (letter) 26(5) 99-102 |
|
Medicines Line
|
| telephone information service 26(4) 90; 25(5) 115 |
|
Medi-List
|
| medication monitoring (letter) 17(4) 79-81 |
|
medroxyprogesterone and conjugated oestrogens
|
| oestradiol combination - hormone replacement - Divina (New drug) 18(3) 58-9 |
| oestrogen combination - Premia (New strength) 24(6) 155-8 |
| Premia Low (New strength) 27(1) 21-3 |
| progestogen-only contraceptives 22(1) 6-8 |
|
MedSafety
|
| online learning system for medication error prevention (letter) 27(5) 109-13 |
|
mefloquine
|
| malaria and travel 25(3) 66-9 |
|
melatonin
|
| physiology 20(4) 98 |
|
Melizide
|
| see glipizide 17(2) 30-2 |
|
meloxicam
|
| osteoarthritis - Mobic (New drug) 25(2) 44-7 |
|
memantine
|
| Ebixa - Alzheimer's disease (New drug) 26(5) 118-9 |
|
memory disorders
|
| neurocognitive effects of chemotherapy 31(1) 22-4 |
|
Mencevax
|
| see meningococcal group C conjugate vaccine 26(3) 56-8; 17(1) 6-8 |
|
Meniere's syndrome
|
| diagnosis and management of dizziness 28(4) 94-7 |
| patient support organisations 28(4) 107 |
|
Meningitec
|
| see meningococcal group C conjugate vaccine 26(3) 56-8; 24(6) 155-8 |
|
meningococcal disease
|
| management 22(5) 117-8 |
| rifampicin and oral contraceptives (letter) 23(2) 27-8 |
| vaccines 26(3) 56-8 |
|
meningococcal vaccines
|
| Mencevax (New drug) 17(1) 6-8 |
| Mencevax, Meningitec, Menjugate, Menomune 26(3) 56-8 |
| Meningitec (New drug) 24(6) 155-8 |
| Menjugate (New formulation) 25(6) 147-51 |
| NeisVac-C (New formulation) 25(6) 147-51 |
| vaccines 26(3) 56-8 |
|
Menjugate
|
| see meningococcal group C conjugate vaccine (New formulation) 26(3) 56-8; 25(6) 147-51 |
|
Menomune
|
| see meningococcal polysaccharide vaccines 26(3) 56-8 |
|
menopause
|
| hormone replacement therapy (editorial) 23(5) 90-2 |
| hormone replacement therapy advice to patients 25(3) 60-2 |
| letters 25(5) 104-7 |
| hormone replacement therapy and risk of thromboembolism 25(3) 57-9 |
| hormone replacement therapy risks and benefits 26(1) 8-10 |
| tibolone - Livial (New drug) 23(4) 84-7 |
|
menorrhagia
|
| levonorgestrel - Mirena (New delivery system) 24(2) 43-7 |
|
menstruation
|
| agnus castus and premenstrual syndrome 24(5) 123 |
|
meropenem
|
| antibiotic - Merrem IV (New drug) 20(2) 45-51 |
|
Merrem IV
|
| see meropenem 20(2) 45-51 |
|
mesalasine
|
| Pentasa, Salofalk (New formulations) 27(4) 101-5 |
| Salofalk (New formulation) 25(4) 94-9 |
|
mesna
|
| new formulation - Uromitexan 20(1) 22-3 |
| uroprotective in cancer chemotherapy - Uromitexan (New drug) 17(1) 6-8 |
|
mesothelioma
|
| pemetrexed disodium - Alimta (New drug) 28(1) 19-23 |
|
meta-analysis
|
| in drug evaluation 20(4) 93-6; 20(3) 61-4 |
|
Metalyse
|
| see tenecteplase 24(2) 43-7 |
|
metformin
|
| Diabex (New strength) 25(4) 94-9 |
| drug interactions 24(4) 83-5 |
| and insulin analogues 25(2) 29-31 |
| letter 25(5) 104-7 |
| Metformin-BC (New brand) 24(4) 100-2 |
| in polycystic ovary syndrome 27(5) 129-31 |
| letter 28(3) 55-8 |
| in pregnancy and lactation 30(3) 68-9 |
| thiazolidinediones 27(3) 70-4 |
| in type 2 diabetes 20(3) 65-7 |
|
methadone
|
| dextromethorphan and serotonin syndrome (letter) 29(6) 149-50 |
| in opioid dependence 24(1) 4-6 |
| letter 24(3) 51-5 |
| in palliative care (letter) 23(5) 93-6 |
|
methotrexate
|
| in adult rheumatoid arthritis 26(2) 36-40 |
| adverse effects 23(2) 44-5 |
| letter 23(5) 93-6 |
|
methyl-5-aminolevulinate
|
| Metvix - skin cancer (New drug) 27(3) 76-9 |
|
methylphenidate
|
| in attention deficit hyperactivity disorder (PBAC question) 24(5) 119 |
| letters 19(3) 59-62; 19(2) 36-8; 19(1) 3-6 |
| Concerta (New brand) 27(2) 50-1 |
| Douglas methylphenidate (New brand) 25(6) 147-51 |
|
metoclopramide
|
| dystonic reactions 24(1) 19-20 |
|
metoprolol succinate
|
| Toprol-XL (New formulation) 27(3) 76-9 |
|
metoprolol tartrate
|
| in heart failure 23(6) 120-3 |
| Metrol (New brand) 27(1) 21-3 |
| SBPA Metoprolol (New brand) 23(1) 21-3 |
|
Metrol
|
| see Metoprolol tartrate 27(1) 21-3 |
|
metronidazole
|
| and breastfeeding (letter) 28(2) 29-33 |
| distribution in human milk 20(2) 35-40 |
|
Metvix
|
| see methyl-5-aminolevulinate 27(3) 76-9 |
|
mianserin
|
| new brand - Lerivon 18(1) 7-9 |
|
mibefradil
|
| angina, hypertension - Posicor (New drug) 21(2) 49-55 |
| when to use a new drug (editorial) 21(3) 67-9 |
|
MIBGen
|
| see iobenguane 27(5) 131-3 |
|
Micardis
|
| see telmisartan 22(6) 147-51 |
|
miconazole
|
| gel - warfarin interaction 26(2) 35 |
|
midazolam
|
| Midazolam Injection BP (New brand) 25(4) 94-9 |
| new strength - Hypnovel 17(2) 30-2 |
|
migraine
|
| alternatives to pethidine 20(3) 71 |
| letter 21(2) 31-4 |
| and analgesic overuse 28(6) 143-5 |
| letter 29(3) 59-62 |
| naratriptan - Naramig (New drug) 21(4) 108-11 |
| sumatriptan - Imigran (New strength) 19(2) 38-40 |
| sumatriptan 50mg tablets (PBAC question) 20(4) 86-7 |
| letter 21(3) 60-3 |
| zolmitriptan - Zomig (New drug) 21(4) 108-11 |
|
milk, human
|
| drug distribution 20(2) 35-40 |
| dental implications 20(2) 51 |
| 'Drugs and breastfeeding' (book review) 27(6) 154 |
| metronidazole (letter) 28(2) 29-33 |
|
mineralocorticoids
|
| pharmacology 19(2) 41-4 |
|
mini-mental state examination
|
| mental status testing in dementia 28(1) 11-3 |
|
Minirin
|
| see desmopressin acetate 26(5) 118-9 |
|
Minulet ED
|
| see gestodene ethinyloestradiol combination 18(1) 7-9 |
|
miotics
|
| in glaucoma 25(6) 142-6 |
|
Mirena
|
| see levonorgestrel 24(2) 43-7 |
|
mirtazapine
|
| Axit (New brand) 27(1) 21-3 |
| depression - Avanza, Remeron (New drug) 24(3) 71-5 |
| Mirtazon (New brand) 25(6) 147-51 |
|
Mirtazon
|
| see mirtazapine 25(6) 147-51 |
|
mite infestations
|
| scabies management 23(2) 33-5 |
|
mitozantrone
|
| Onkotrone (New strength) 24(4) 100-2 |
|
Mivacron
|
| see mivacurium chloride 19(2) 38-40 |
|
mivacurium chloride
|
| neuromuscular blocker - Mivacron (New drug) 19(2) 38-40 |
|
Mobic
|
| see meloxicam 25(2) 44-7 |
|
moclobemide
|
| Arima (New brand) 23(3) 64-7 |
| costs and benefits of antidepressants (editorial) 18(4) 82-4 |
| dietary restrictions and tyramine interactions (letters) 17(2) 28-9 |
| DBL Moclobemide (New brand) 23(2) 45-6 |
| interaction with antidepressants 18(4) 100-1 |
| letter 19(2) 36-8 |
| Moclobemide-BC (New brand) 24(4) 100-2 |
| and new antidepressants 22(5) 108-11 |
| product information (letter) 22(1) 3-5 |
| product information (letter) 21(3) 60-3 |
| review of new antidepressants 18(4) 92-6 |
| letters 19(2) 36-8 |
| tricyclic antidepressant overdoses (letter) 17(2) 28-9 |
|
modafinil
|
| narcolepsy - Modavigil (New drug) 25(5) 120-3 |
|
Modavigil
|
| see modafinil 25(5) 120-3 |
|
modified bovine lung extract
|
| respiratory distress syndrome - Survanta (New drug) 18(1) 7-9 |
|
molecular genetics
|
| glossary of terminology 21(3) 69-71 |
|
mometasone
|
| Allermax (New brand) 24(2) 43-7 |
| dietary restrictions and tyramine interactions (letters) 17(2) 28-9 |
| Nasonex - (New formulation) 22(5) 125-7 |
| steroid responsive dermatoses - Elocon (New drug) 17(1) 6-8 |
|
monoamine oxidase inhibitors - see also antidepressants; moclobemide
|
| in Parkinson's disease 17(1) 21-3 |
|
monoclonal antibodies
|
| abciximab - non-malignant disease 29(5) 130-3 |
| adalimumab |
| Humira - rheumatoid arthritis (New drug) 27(4) 101-5 |
| tumour necrosis factor blockers - rheumatoid arthritis 27(2) 43-6 |
| alemtuzumab - MabCampath - chronic lymphocytic leukaemia (New drug) 29(6) 167-71 |
| basiliximab - non-malignant disease 29(5) 130-3 |
| bevacizumab - Avastin - colorectal cancer (New drug) 28(4) 104-6 |
| daclizumab - non-malignant disease 29(5) 130-3 |
| efalizumab - Raptiva - psoriasis (New drug) 28(1) 19-23 |
| infliximab |
| Remicade - Crohn's disease 24(2) 43-7 |
| tumour necrosis factor blockers - rheumatoid arthritis 27(2) 43-6 |
| muromonab - non-malignant disease 29(5) 130-3 |
| natalizumab |
| multiple sclerosis - Tysabri (New drug) 30(4) 107-11 |
| non-malignant disease 29(5) 130-3 |
| in non-malignant disease 29(5) 130-3 |
| omalizumab - anti-IgE monoclonal antibody - Xolair (New drug) 26(6) 146-51 |
| ranibizumab - macular degeneration - Lucentis (New drug) 30(3) 79-82 |
| rituximab - non-malignant disease 29(5) 130-3 |
| trastuzumab - breast cancer 26(6) 141-3 |
|
Monoplus
|
| see fosinopril sodium/hydrochlorothiazide 23(6) 137-9 |
|
montelukast
|
| anti-leukotriene drugs in asthma 22(3) 58-60 |
| letter 22(6) 131-2 |
| asthma - Singulair (New drug) 21(4) 108-11 |
| leukotriene clinical pharmacology 22(3) 55-7 |
| Singulair (New strength) 24(4) 100-2 |
|
moroctocog
|
| haemophilia A - Refacto (New drug) 25(4) 94-9 |
|
morphine
|
| MS Mono (New formulation) 24(1) 20-3 |
| new formulation - Kapanol 17(4) 87-90 |
| new strength - MS Contin 20(1) 22-3 |
| in palliative care 23(5) 93-6; 19(3) 66-8 |
| letter - dosage forms 20(1) 3-4 |
| pharmacology 19(3) 63-5 |
| prescription statistics 19(3) 68 |
| Schedule of Pharmaceutical Benefits (PBAC question) 19(4) 101-3 |
|
motor neurone disease
|
| riluzole (New drug) 25(4) 94-9 |
|
mouth
|
| drug and radiotherapy-induced xerostomia 29(4) 97-8 |
| dental notes 29(4) 108 |
| letters 30(1) 3-4 |
|
movement disorders
|
| dystonic reactions to drugs 24(1) 19-20 |
| positron emission tomography 18(1) 15-8 |
|
moxifloxacin
|
| antibiotic - Avelox (New drug) 24(6) 155-8 |
| pneumonia (Underneath the RADAR) 26(6) 131 |
|
moxonidine
|
| Physiotens - hypertension (New drug) 29(1) 25-7 |
|
MS Contin
|
| see morphine 20(1) 22-3 |
|
MS Mono
|
| see morphine 24(1) 20-3 |
|
mucopolysaccharidosis I
|
| laronidase - Aldurazyme (New drug) 30(3) 79-82 |
|
MultiHance
|
| see gadobenate dimeglumine 27(6) 159-65 |
|
multiple sclerosis
|
| glatiramer - Copaxone (New drug) 22(6) 147-51 |
| immune-modulating drugs 25(2) 32-5 |
| interferon beta-1a - Avonex (New drug) 22(2) 43-7 |
| interferon beta-1b - Betaferon (New drug) 19(1) 24-7 |
| magnetic resonance imaging in neuroradiology 31(1) 18-20 |
| natalizumab - Tysabri (New drug) 30(4) 107-11 |
| patient perspective 25(2) 35-6 |
| patient support organisations 25(2) 36-7 |
|
mumps
|
| childhood immunisation 17(4) 91-4 |
| measles, mumps, rubella vaccine - Priorix (New formulation) 22(4) 95-8 |
|
mupirocin
|
| Bactroban (New formulation) 21(4) 108-11 |
|
muscle disorders
|
| cerivastatin/gemfibrozil combination 24(5) 109 |
| and statins 28(4) 102 |
| letter 28(6) 136-9 |
| statins and muscle damage (editorial) 26(4) 74-5 |
|
muscle symptoms
|
| with simvastatin (medicinal mishap) 28(4) 102 |
|
MUSE
|
| see alprostadil 22(2) 43-7 |
|
mushroom poisoning
|
| Amanita phalloides 23(2) 29 |
|
mutations
|
| gene therapy 20(3) 72-3 |
| genetic testing 18(3) 76-9; 18(2) 45-8 |
|
myasthenia gravis
|
| Australian Myasthenic Association in NSW 30(6) 160 |
| dental notes 30(6) 160 |
| patient's perspective 30(6) 161 |
| treatment 30(6) 156-60 |
|
Mycobacterium infections
|
| rifabutin - Mycobutin (New drug) 17(4) 87-90 |
|
Mycobutin
|
| see rifabutin 17(4) 87-90 |
|
mycophenolate mofetil
|
| CellCept (New formulation) 23(3) 64-7 |
| kidney transplantation - CellCept (New drug) 20(2) 45-51 |
| pharmacology of immunosuppressants 29(4) 99-101; 29(4) 102-8 |
|
mydriatics
|
| flurbiprofen - Ocufen (New drug) 17(1) 6-8 |
|
myeloma, multiple
|
| bortezomib - Velcade (New drug) 29(3) 84-7 |
| thalidomide - Thalidomide Pharmion (New drug) 26(6) 146-51 |
|
myocardial infarction - see also coronary disease
|
| ACE inhibitors in heart failure (editorial) 19(1) 2-3 |
| antiplatelet drugs 19(4) 98-101 |
| and calcium channel antagonists (editorial) 22(1) 2-3; 19(2) 35 |
| cardiac markers - abnormal laboratory results 26(4) 88-90 |
| clopidogrel - antiplatelet drug - Plavix (New drug) 22(2) 43-7 |
| early management 19(2) 52-4 |
| eplerenone - Inspra (New drug) 28(5) 130-1 |
| letter 29(2) 32-5 |
| eptifibatide - antiplatelet drug - Integrilin (New drug) 26(6) 146-51 |
| HMG CoA reductase inhibitors (editorial) 21(4) 86-7 |
| HMG CoA reductase inhibitors - clinical trials 22(5) 114-7 |
| letter 22(6) 131-2 |
| management 24(3) 56-8 |
| management of post infarct patients 19(1) 8-10 |
| dental implications 19(1) 13 |
| reteplase - Rapilysin (New drug) 21(3) 80-3 |
| tenecteplase - thrombolysis - Metalyse (New drug) 24(2) 43-7 |
| tirofiban - antiplatelet drug - Aggrastat (New drug) 22(4) 95-8 |
|
myopathy
|
| cerivastatin/gemfibrozil combination 24(5) 109 |
Home
